Enhanced Histone H3.3-K27M Neoantigen Vaccine Therapy Against Diffuse Intrinsic Pontine Glioma (ENACTING)- A Phase I Clinical Trial
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Histone H3.3-K27M Neoantigen Vaccine - TCRCure Biopharma (Primary)
- Indications Diffuse intrinsic pontine glioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENACTING
- 25 Jul 2023 Planned End Date changed from 1 Apr 2024 to 1 Dec 2024.
- 25 Jul 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Mar 2024.
- 06 Jun 2023 Preliminary findings of a phase I trial studying a neoantigen peptide vaccine targeting H3.3-K27M presented at the 59th Annual Meeting of the American Society of Clinical Oncology